Promising New Treatment for Severe Epilepsy

A new method to reduce the epileptic activity in the specific areas of the brain and nerve cells by using chemogenetics was discovered by a team of researchers at Lund University in Sweden. "In mice studies, we succeeded in reducing //seizure activity by intervening in an area of the brain that is not the focus of the epileptic seizures but is directly connected to it through a network of neurons. If we get the same result in further, long-term studies, it could pave the way for treatment of severe epilepsy", says Mérab Kokaia, professor, and director of the Epilepsy Centre at Lund University.

In the study, published in the research journal Scientific Reports, researchers succeeded in reducing epileptic activity in the hippocampus, an area of the brain which is important for memory and learning, among other things. In the most severe cases, this is exactly the part of the brain where epileptic seizures usually start.

The research team used a method known as chemogenetics, which enables them to reduce activity in the specific areas and nerve cells involved in an epileptic seizure, whereas other parts and cells in the body remain unaffected. This is in contrast to current drugs that affect more or less all parts and cells of the body, potentially leading to side-effects.

"Very few similar studies have been carried out previously, and this is the first study in which we succeeded in reducing the epileptic activity in one area of the brain by using chemogenetics to affect another area, not the seizure focus. This opens up the possibility of treating epilepsy in areas of the brain that cannot be surgically removed or treated directly", explains Mérab Kokaia.

In Sweden, around 60 000 people currently suffer from epilepsy, of whom around a third have such a severe form of the disease that current treatment with existing drugs does not work.

"We hope that, in the future, this knowledge will help people with this severe form of epilepsy, but also that it will benefit other patients with the disease," concludes Mérab Kokaia.

Advertisement

Source-Eurekalert